JP2018506994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506994A5 JP2018506994A5 JP2017562129A JP2017562129A JP2018506994A5 JP 2018506994 A5 JP2018506994 A5 JP 2018506994A5 JP 2017562129 A JP2017562129 A JP 2017562129A JP 2017562129 A JP2017562129 A JP 2017562129A JP 2018506994 A5 JP2018506994 A5 JP 2018506994A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- semaphorin
- functional fragment
- hydrophilic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims description 66
- 150000001413 amino acids Chemical class 0.000 claims description 64
- 102000014105 Semaphorin Human genes 0.000 claims description 57
- 108050003978 Semaphorin Proteins 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 44
- 150000007523 nucleic acids Chemical group 0.000 claims description 42
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 16
- 235000004279 alanine Nutrition 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 102000009203 Sema domains Human genes 0.000 claims description 7
- 108050000099 Sema domains Proteins 0.000 claims description 7
- 238000006471 dimerization reaction Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 230000001613 neoplastic effect Effects 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 102100027974 Semaphorin-3A Human genes 0.000 claims description 5
- 108010090319 Semaphorin-3A Proteins 0.000 claims description 5
- 102100027979 Semaphorin-3B Human genes 0.000 claims description 5
- 101710199438 Semaphorin-3B Proteins 0.000 claims description 5
- 102100027980 Semaphorin-3C Human genes 0.000 claims description 5
- 101710199433 Semaphorin-3C Proteins 0.000 claims description 5
- 102100027746 Semaphorin-3D Human genes 0.000 claims description 5
- 101710199434 Semaphorin-3D Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- 230000002491 angiogenic effect Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 2
- 238000010606 normalization Methods 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 102000002022 plexin Human genes 0.000 claims description 2
- 108050009312 plexin Proteins 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 6
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15156195.8 | 2015-02-23 | ||
| EP15156195 | 2015-02-23 | ||
| PCT/EP2016/053750 WO2016135130A1 (en) | 2015-02-23 | 2016-02-23 | Non-natural semaphorins 3 and their medical use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506994A JP2018506994A (ja) | 2018-03-15 |
| JP2018506994A5 true JP2018506994A5 (https=) | 2019-04-11 |
| JP6959869B2 JP6959869B2 (ja) | 2021-11-05 |
Family
ID=52596769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562129A Active JP6959869B2 (ja) | 2015-02-23 | 2016-02-23 | 非天然セマフォリン３およびそれらの医学的使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10906948B2 (https=) |
| EP (1) | EP3262064A1 (https=) |
| JP (1) | JP6959869B2 (https=) |
| KR (1) | KR20170138410A (https=) |
| CN (1) | CN107810192A (https=) |
| AU (1) | AU2016223584B2 (https=) |
| BR (1) | BR112017017825A2 (https=) |
| CA (1) | CA2976593A1 (https=) |
| IL (1) | IL253872B (https=) |
| RU (1) | RU2722832C2 (https=) |
| SG (1) | SG11201706211PA (https=) |
| WO (1) | WO2016135130A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017000059A1 (en) | 2015-06-29 | 2017-01-05 | The University Of British Columbia | B1sp fusion protein therapeutics, methods, and uses |
| EP3321683A4 (en) * | 2015-07-09 | 2018-11-21 | Juntendo Educational Foundation | Method for evaluating lymph node metastatic potential of endometrial cancer |
| WO2019207051A1 (en) | 2018-04-25 | 2019-10-31 | Università Degli Studi Di Torino | Medical use of combinations of non-natural semaphorins 3 and antimetabolites |
| CN109821009B (zh) * | 2019-01-22 | 2020-03-31 | 南京医科大学 | 轴突导向因子重组蛋白Semaphorin3G的医药用途 |
| CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
| CN110684805B (zh) * | 2019-11-19 | 2023-08-01 | 四川大学华西医院 | 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用 |
| CN111009287B (zh) * | 2019-12-20 | 2023-12-15 | 东软集团股份有限公司 | SLiMs预测模型的生成方法、装置、设备和存储介质 |
| WO2021245670A1 (en) * | 2020-06-04 | 2021-12-09 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Modified semaphorin 3a, compositions comprising the same and uses thereof |
| CN112687338B (zh) * | 2020-12-31 | 2022-01-11 | 云舟生物科技（广州）有限公司 | 基因序列的存储和还原方法、计算机存储介质及电子设备 |
| CN116650481B (zh) * | 2021-12-10 | 2024-06-14 | 中南大学湘雅医院 | 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用 |
| AU2022415337A1 (en) * | 2021-12-14 | 2024-08-01 | Daniel Pierce RADIN | Compositions and methods for treating cancers of the central nervous system (cns), including glioblastoma and chemoresistant cns tumors, and related compositions and methods for inhibiting and eliminating cns cancer stem cells |
| CN115947817B (zh) * | 2023-02-22 | 2024-07-02 | 甘肃中肽生物科技有限公司 | 一种肿瘤相关多肽及其制备方法和应用 |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
| CN119464491B (zh) * | 2024-10-28 | 2025-09-09 | 中山大学 | circSEMA3C编码SEMA-123aa在膀胱癌淋巴转移靶向治疗中的作用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5639856A (en) * | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| EP1216258A1 (en) | 1999-09-28 | 2002-06-26 | Universität Zürich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US7290975B2 (en) | 2001-03-17 | 2007-11-06 | Mechanical Tech & Engineering Co. | Two-speed passenger lift and pump assembly therefor |
| US7781413B2 (en) | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
| US7184284B2 (en) | 2004-03-30 | 2007-02-27 | Micron Technology, Inc. | Closed-loop high voltage booster |
| EP1962961B1 (en) | 2005-11-29 | 2013-01-09 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| SG178744A1 (en) * | 2007-02-02 | 2012-03-29 | Biogen Idec Inc | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
| EP2781223B1 (en) * | 2007-10-19 | 2017-02-22 | Rappaport Family Institute for Research in the Medical Sciences | Compositions comprising semaphorins for use in the treatment of cancer |
| WO2011066284A1 (en) * | 2009-11-25 | 2011-06-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
| EP3677310A1 (en) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
-
2016
- 2016-02-23 RU RU2017128465A patent/RU2722832C2/ru active
- 2016-02-23 US US15/552,511 patent/US10906948B2/en active Active
- 2016-02-23 EP EP16709710.4A patent/EP3262064A1/en active Pending
- 2016-02-23 CN CN201680011456.5A patent/CN107810192A/zh active Pending
- 2016-02-23 CA CA2976593A patent/CA2976593A1/en active Pending
- 2016-02-23 WO PCT/EP2016/053750 patent/WO2016135130A1/en not_active Ceased
- 2016-02-23 BR BR112017017825-7A patent/BR112017017825A2/pt not_active IP Right Cessation
- 2016-02-23 KR KR1020177026803A patent/KR20170138410A/ko not_active Ceased
- 2016-02-23 JP JP2017562129A patent/JP6959869B2/ja active Active
- 2016-02-23 SG SG11201706211PA patent/SG11201706211PA/en unknown
- 2016-02-23 AU AU2016223584A patent/AU2016223584B2/en active Active
-
2017
- 2017-08-07 IL IL253872A patent/IL253872B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506994A5 (https=) | ||
| CN114206932B (zh) | 修饰的双特异性抗cd3抗体 | |
| JP2023112192A (ja) | サイトカイン融合タンパク質 | |
| KR102354845B1 (ko) | 인간화 항 clever-1 항체 및 이의 용도 | |
| JP2020508329A5 (https=) | ||
| RU2017128465A (ru) | Неприродные семафорины класса 3 и их медицинское применение | |
| EA014226B1 (ru) | Антитела к cd154, их фрагменты и способы применения антител и фрагментов | |
| TW201526915A (zh) | 抗ａｎｇ２抗體與ｃｄ４０促效劑之組合療法 | |
| JP2014158480A5 (https=) | ||
| TW200922616A (en) | FOXM1 peptide and medicinal agent comprising the same | |
| CN107531787B (zh) | 靶向cd1d的单域抗体 | |
| CN115666631A (zh) | Cd40结合蛋白 | |
| US20110059045A1 (en) | Pharmaceutical composition for cancer treatment | |
| EP4043482A2 (en) | Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof | |
| CN100549175C (zh) | 一种具有抑癌作用的重组蛋白及其编码基因与应用 | |
| TW202309072A (zh) | 編碼重組轉形生長因子(TGF)-β單體之溶瘤病毒及其用途 | |
| AU2003288434B2 (en) | Peptides, antibodies thereto, and their use in the treatment of central nervous system damage | |
| US20240317889A1 (en) | Anti-her-2 antibody-chemokine fusion protein, preparation method therefor and application thereof | |
| JP2020501518A (ja) | キメラタンパク質を用いたアレルギー疾患の治療 | |
| CN114450068A (zh) | 用于治疗急性神经炎性损伤的方法和剂 | |
| CN108295242B (zh) | 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用 | |
| US11021541B2 (en) | Method of inhibiting the gonadotropin-releasing hormone (GnRH) receptor by administering a GHR-106 monoclonal antibody | |
| JP4991544B2 (ja) | ストレス応答を媒介するためのペプチド阻害剤 | |
| CN118369123A (zh) | 用于有效载荷的体内靶向递送的四嗪缀合物 | |
| WO2020098785A1 (zh) | 人源化抗人pd-l1单克隆抗体及其制备方法和用途 |